20
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      Are you tired of sifting through news that doesn't interest you?
      Personalize your Karger newsletter today and get only the news that matters to you!

      Sign up

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Hidradenitis suppurativa (HS) is a neglected chronic inflammatory disease with long delay in diagnosis. Besides pain, purulent discharge, and destruction of skin architecture, HS patients experience metabolic, musculoskeletal, and psychological disorders.

          Objectives

          To determine the delay in HS diagnosis and its consequences for patients and the healthcare system.

          Methods

          This was a prospective, multicenter, epidemiologic, non-interventional cross-sectional trial carried out in Germany and based on self-reported questionnaires and medical examinations performed by dermatologists. In total, data of 394 adult HS patients were evaluated.

          Results

          The average duration from manifestation of first symptoms until HS diagnosis was 10.0 ± 9.6 (mean ± SD) years. During this time, HS patients consulted on average more than 3 different physicians − most frequently general practitioners, dermatologists, surgeons, gynecologists − and faced more than 3 misdiagnoses. Diagnosis delay was longer in younger and non-smoking patients. In most cases, HS was correctly diagnosed by dermatologists. The longer the delay of diagnosis, the greater the disease severity at diagnosis. Delayed HS diagnosis was also associated with an increased number of surgically treated sites, concomitant diseases, and days of work missed.

          Conclusion

          This study demonstrates an enormous delay in the diagnosis of HS, which results in more severe disease. It also shows for the first time that a delay in diagnosis of a chronic inflammatory disease leads to a higher number of concomitant systemic disorders. In addition to the impaired health status, delayed diagnosis of HS was associated with impairment of the professional life of affected people.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Hidradenitis suppurativa

          Hidradenitis suppurativa (HS; also designated as acne inversa) is a chronic inflammatory disorder, which affects the intertriginous skin and is associated with numerous systemic comorbidities. The estimated prevalence of HS is ~1% in most studied countries. Typically starting in early adulthood, cutaneous inflamed nodules, abscesses and pus-discharging tunnels develop in axillary, inguinal, gluteal and perianal body sites. The comorbidities of HS include metabolic and cardiovascular disorders, which contribute to reduced life expectancy. A genetic predisposition, smoking, obesity and hormonal factors are established aetiological factors for HS. Cutaneous changes seem to start around hair follicles and involve activation of cells of the innate and adaptive immune systems, with pivotal roles for pro-inflammatory cytokines such as tumour necrosis factor, IL-1β and IL-17. The unrestricted and chronic immune response eventually leads to severe pain, pus discharge, irreversible tissue destruction and scar development. HS has profound negative effects on patients' quality of life, which often culminate in social withdrawal, unemployment, depression and suicidal thoughts. The therapeutic options for HS comprise antibiotic treatment, neutralization of tumour necrosis factor and surgical intervention together with lifestyle modification. Nevertheless, there is an enormous need for awareness of HS, understanding of its pathogenesis and novel treatments.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences

            Psoriasis is a common inflammatory skin disease characterized by the appearance of red scaly plaques that can affect any part of the body. High prevalence, chronicity, disfiguration, disability, and associated comorbidity make it a challenge for clinicians of multiple specialties. Likewise, its complex pathogenesis, comprising inflammation, hyperproliferation, and angioneogenesis, intrigues numerous scientific disciplines, namely, immunology. From a clinical perspective, the severity of psoriasis is highlighted by its increased mortality, with cardiovascular diseases contributing the highest excess risk. From a scientific point of view, psoriasis has to be considered a systemic inflammatory condition, as blood biomarkers of inflammation are elevated and imaging techniques document sites of inflammation beyond the skin. While the association of psoriasis with cardiovascular diseases is now widely accepted, causes and consequences of this association are controversially discussed. This review comments on epidemiologic, genetic, and mechanistic studies that analyzed the relation between psoriasis and cardiovascular comorbidity. The hypothesis of psoriasis potentially being an independent cardiovascular risk factor, driving atherosclerosis via inflammation-induced endothelial dysfunction, will be discussed. Finally, consequences for the management of psoriasis with the objective to reduce the patients’ excess cardiovascular risk will be pointed out.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study

              Aims The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI, in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). We hypothesized that we would observe a reduction in inflammatory-driven phenotypes of coronary plaque, including non-calcified coronary plaque burden and lipid-rich necrotic core in those treated with biologic therapy after one-year compared with non-biologic therapy. Methods and results In a prospective, observational study, 290 participants were recruited from 1 January 2013 through 31 October 2018 with 215 completing one-year follow-up. Of the 238, 121 consecutive participants who were biologic treatment naïve at baseline were included. A blinded reader (blinded to patient demographics, visit and treatment) quantified total coronary plaque burden and plaque subcomponents (calcified and non-calcified) in the three main coronary vessels >2 mm using dedicated software (QAngio, Medis, Netherlands). Psoriasis patients were middle-aged [mean (standard deviation) age, 50.5 (12.1) years], mostly male ( n = 70, 58%) with low cardiovascular risk by Framingham score [median (interquartile range, IQR), 3 (1–6)] and had moderate to severe skin disease at baseline [median (IQR) Psoriasis Area Severity Index, PASI, 8.6 (5.3–14.0)]. Biologic therapy was associated with a 6% reduction in non-calcified plaque burden ( P = 0.005) reduction in necrotic core ( P = 0.03), with no effect on fibrous burden ( P = 0.71). Decrease in non-calcified plaque burden in the biologic treated group was significant compared with slow plaque progression in non-biologic treated (Δ, −0.07 mm 2 vs. 0.06 mm 2 ; P = 0.02) and associated with biologic treatment beyond adjustment for traditional cardiovascular risk factors ( β = 0.20, P = 0.02). Conclusion In this observational study, we demonstrate that biologic therapy in severe psoriasis was associated with favourable modulation of coronary plaque indices by CCTA. These findings highlight the importance of systemic inflammation in coronary artery disease and support the conduct of larger, randomized trials.
                Bookmark

                Author and article information

                Journal
                Dermatology
                Dermatology
                DRM
                Dermatology (Basel, Switzerland)
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
                1018-8665
                1421-9832
                September 2020
                1 July 2020
                1 July 2020
                : 236
                : 5
                : 421-430
                Affiliations
                [1] aInterdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité − Universitätsmedizin Berlin, Berlin, Germany
                [2] bPsoriasis Research and Treatment Centre, Charité − Universitätsmedizin Berlin, Berlin, Germany
                [3] cBerlin-Brandenburg Centre for Regenerative Therapies, Charité − Universitätsmedizin Berlin, Berlin, Germany
                [4] dCentre for Dermatosurgery, Havelklinik, Berlin, Germany
                [5] eGKM Gesellschaft für Therapieforschung mbH, Munich, Germany
                [6] fAbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
                Author notes
                *Robert Sabat, Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité − Universitätsmedizin Berlin, Charitéplatz 1, DE–10117 Berlin (Germany), robert.sabat@ 123456charite.de
                Article
                PMC7592906 PMC7592906 7592906 drm-0236-0421
                10.1159/000508787
                7592906
                32610312
                aeb12784-3d24-488d-aa35-df196f477d7e
                Copyright © 2020 by S. Karger AG, Basel
                History
                : 18 February 2020
                : 26 April 2020
                : 2020
                Page count
                Figures: 6, Tables: 1, References: 33, Pages: 10
                Categories
                Research Article

                Healthcare system,Acne inversa,Hidradenitis suppurativa,Comorbidity,Diagnosis

                Comments

                Comment on this article